HPP8668 / vTv Therapeutics - LARVOL DELTA

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease (GlobeNewswire) - "Preclinical studies conducted at Augusta University using the Townes sickle cell disease mouse model showed that HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood cell sickling....HPPD (HPP8668) is an investigational, oral, first-in-class Nrf2/Bach1 modulator being developed by vTv Therapeutics for the treatment of sickle cell disease."

Orphan drug • Preclinical • Sickle Cell Disease

vTv Therapeutics Inc...company announced on Wednesday evening that the FDA granted orphan drug designation to HPPD, its oral Nrf2/Bach1 modulator being investigated as a treatment for sickle cell disease. (Investing.com)

Orphan drug • Sickle Cell Disease